The subject expert committee (SEC) has asked Roche to conduct a phase 4 study in India and, accordingly, the company should submit a protocol for the study within three months of the grant of permissi ...

Along with haemolysis, people with PNH can suffer life-threatening blood clots and impaired bone marrow function. The median survival after diagnosis is 10 years, although some patients can ...

PNH is a rare, life-threatening disease of the blood characterised by destruction of red blood cells, blood clots and impaired bone marrow function, causing fatigue, recurrent infections and ...

Basel, 05 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66 th American Society of Hematology ...

PMID 30055352. Summary: This study by Amy DeZern, Robert Brodsky and Richard Jones explores whether eculizumab affects the success of bone marrow transplant in patients with severe aplastic anemia and ...

For months, doctors in Michigan had been searching for a bone marrow donor for a 68-year-old African American patient. She had been treated for acute myeloid leukemia once before, but the fast ...

This first-in-class, oral Factor D inhibitor can now be used as an add-on to ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults with residual haemolytic ...

Gifting allows recipients to access the article for free. Ping Ho, the founder and CEO of Marrow parent Backbone Hospitality, announced Marrow's first suburban shop in February. The 1,400-square ...

AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading and diverse pipeline in hematology at the 66th American Society of Hematology (ASH) Annual Meeting ...